Autolus Announces Publication of a Unique Therapeutic Approach for Treatment of Patients with T-Cell Lymphomas in Nature Medicine

Published 14 Nov 2017

Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of an article in Nature Medicine describing a unique targeting strategy for the treatment of patients with T-cell lymphomas.

T-cell lymphomas are a family of rare and aggressive cancers for which there are few treatment options. A key challenge of treating these cancers has been to identify a target that would allow the elimination of T-cell lymphoma while sparing healthy T-cells, as these play an essential role in providing protection against infections.

Dr Paul Maciocia and his co-authors* describe a new targeting approach based on the mutually exclusive expression of two subtypes of the T-cell receptor beta chain (TRBC1 and TRBC2). Normal T-cells contain both TRBC1 and TRBC2 compartments whereas T-cell Lymphoma cells express only TRBC1 or TRBC2 due to clonal origin and evolution of those cancerous cells.

As proof of concept for anti-TRBC immunotherapy, the team developed anti-TRBC1 CAR Tcells, which recognise and kill normal and malignant TRBC1 but not TRBC2 T-cells in mouse models of T-cell Lymphoma. Unlike non-selective approaches targeting the entire T-cell population, this approach eradicates a portion of T-cells containing the malignancy while preserving a healthy T-cell sub-population to preserve cellular immunity.

This work forms the scientific basis for AUTO4, a unique CAR T-cell product developed by Autolus to target TRBC1, which is due to enter the clinic in the coming months.

The full manuscript “Targeting T-cell receptor ß-constant for immunotherapy of T-cell malignancies” can be found in the December 2017 issue of Nature Medicine –

Commenting on the publication, Dr Julie Vose, Chief, Division of Hematology/ Oncology, Professor of Medicine, Nebraska Medical Center said:

“T-cell lymphomas are blood cancers characterized by a very poor prognosis, particularly after a patient relapses following initial treatment. Unlike other blood cancers, it is not possible to use agents that totally remove all of the cell-type containing the malignancy as Tcells are needed to fight infections. This highly innovative approach addresses this challenge elegantly by selectively removing the portion of the T-cells containing the cancer while leaving a healthy T-cell population intact to provide protection against infection. Consequently, it offers real promise as a potential treatment for this aggressive form of cancer.”

Further information

JW Communications +44 (0)7818 430877
Julia Wilson

* Paul M. Maciocia, Patrycja A. Wawrzyniecka Brian Philip, University College London, Cancer Institute, London, UK
Ida Ricciardelli, University College London, Institute of Child Health, London, UK
Ayse U. Akarca, University College London, Cancer Institute, London, UK
Shimobi Onuoha, Autolus Ltd, London, UK
Mateusz Legut, David K. Cole, Andrew K. Sewell, Division of Infection and Immunity, Cardiff University School of Medicine, UK
Giuseppe Gritti, Department of Haematology, Papa Giovanni XXII Hospital, Milan, Italy
Joan Somja, Department of Anatomy and Cellular Pathology, University of Liege, Belgium
Miguel A. Piris, Anatomical Pathology Service, University Hospital Marques de Valdecilla (IFIMAV), Santander, Spain
Karl S. Peggs, David C. Linch, University College London, Cancer Institute, London, UK
Teresa Marafioti, University College London, Cancer Institute, London, UK
Martin A. Pule, University College London, Cancer Institute, and Autolus Ltd, London, UK

About Autolus

Autolus is a clinical-stage, biopharmaceutical Company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours. For further information please visit the Company’s website at:

About T-Cell Lymphoma

Lymphoma is the most common blood cancer. It occurs when cells of the immune system called lymphocytes, a type of white blood cell, grow and multiply uncontrollably. Cancerous lymphocytes can travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood, or other organs, and form a tumour.

Non-Hodgkin’s Lymphoma (NHL) is the most common classification of lymphoma and makes up approximately 4% of all cancers cases in the UK. Lymphomas can originate from two types of lymphocytes, B-cells and T-cells, with T-cell lymphomas being relatively rarer and accounting for only about 15% of NHL.

There are multiple sub-types of T-cell lymphomas, all with relatively poor prognosis. Current treatment options are not very effective. The NCCN guidelines recommend clinical investigation as a preferred option when patients progress after initial treatment.

Autolus gratefully acknowledges the support of The Wellcome Trust and Cancer Research UK who partially-funded some of the early work on this product.

Syncona Limited Disclaimer

Please read the below disclaimer carefully. You will be asked to accept these terms and conditions before proceeding.

The information on this website is directed only at persons who are shareholders in Syncona Limited (the “Company”) and is provided for their exclusive use and benefit.

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained herein. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so. No information, materials or opinions contained on this website (“Materials”) constitute or would be deemed to constitute a recommendation or invitation in any jurisdiction to invest or otherwise deal in the shares of the Company (the “Shares”).

The website that you are seeking to access does not constitute an offer to buy or sell the securities mentioned in the website in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, the securities mentioned in the website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and other securities laws. There will be no public offer of these securities in the United States. Offers and sales of these securities, and distribution of the related information, may also be subject to restrictions in other jurisdictions.

The website that you are seeking to access is not directed at and may not be viewed by or distributed to persons:

  • in the United States or who are U.S persons (as defined in Rule 902 under the Securities Act);


  • located in a jurisdiction where it is not lawful to access the materials.

The Materials are provided on an “as is” and “as available basis” and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, investment, legal, tax or other advice and is not to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.

The Materials on this website are provided for your personal use and informational purposes only and are subject to change without notice. The Company has the right to suspend or withdraw the provision of all or any of the website of the Materials without prior notice at any time.

The value of investments mentioned in this site, and the income from them may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase.
The Company is a registered closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (the ‘‘POI Law’’) and the Registered Collective Investment Scheme Rules 2008 (the ‘‘CIS Rules’’) issued by the Guernsey Financial Services Commission (the ‘‘GFSC’’). Neither the GFSC nor the States of Guernsey Policy Council take any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it.


Copyright of all images and text in this website is owned by or licensed to the Company or one of its affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use. Any other use is prohibited unless you first request and obtain the prior written consent of the Company. You may not alter or otherwise make any changes to any material that you print or download from this website, including, without limitation, removing any identifying marks or legends from such material. In particular, you may not copy or use any part of this website on any other website, or link any other website to this website, without the prior written permission of the Company. You may not use the website for any purpose which is unlawful, abusive, libellous, obscene or threatening.

No Warranty

The Materials contained in this website are provided without any warranty of any kind, either expressed or implied, to the fullest extent permissible pursuant to applicable law. Neither the Company nor its affiliates assume any responsibility for the uninterrupted availability of this website or warrant that it will be error-free, that defects will be corrected, or that this website or the servers that make it available will be free of viruses or other harmful components.

Liability Waiver

You agree that under no circumstances, including, but not limited to, negligence, shall the Company or any of its affiliates be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the Materials on this website. This does not exclude or restrict any duty or liability that the Company has to its customers under the regulatory system in the United Kingdom or Guernsey.

Privacy Policy

This policy sets out what the Company and its affiliates do with any personal information collected from this website.

Any personal information collected from this website will be processed in accordance with relevant data protection laws.

You may use the public areas of this website without providing the Company or its affiliates with any personal information and the Company and its affiliates do not monitor or collect any personal information through your access to the public areas of this website. The Company and its affiliates do not use cookies to collect information but may gather other anonymous information to assist in improving the services.

If you chose to provide the Company and its affiliates with personal information, this information will only be used for the purposes of the service that you have requested. The Company and its affiliates will not sell or transfer any personal information to third parties without your permission, other than as required by law.

The Company and its affiliates are not responsible for the content or privacy policies of websites to which this website may link.

The Company and its affiliates are committed to protecting your personal information but in the event that the system is infiltrated by unauthorised third parties the Company and its affiliates will not be liable for any resulting misuse of personal information.

Linked Sites

The Company has not reviewed any website linked to this website and is not responsible for the contents of off-site pages or any other websites linked or linking to this website. If you follow any links from this website you do so at your own risk.

Links to this website may not be established without the prior written consent of the Company.

Governing Law

The terms and conditions of this legal notice shall be governed by and construed in accordance with the laws of Guernsey. Users of this website agree that any dispute or action arising out of or relating to these terms or any user’s use of this website shall be commenced only in the courts located in Guernsey, and users of this website hereby consent and submit to the exclusive jurisdiction of such courts for the purposes of any such dispute or action.

By accessing Materials on this website you agree to be bound by the foregoing limitations.